Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| Thursday, June 27th | 2pm ET / 11am PT | SPONSORED BY: KONY SOLUTIONS
The mobile health market is moving rapidly, with apps now helping patients collect health data and physicians tapping into that data remotely. Join as we examine mobile health advances, patient privacy challenges, and how the FDA is evolving its thinking on regulating mobile apps. Register Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 90,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!